Misplaced Pages

Cycloastragenol

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from TA-65)
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
This article's factual accuracy is disputed. Please help to ensure that disputed statements are reliably sourced. (October 2014) (Learn how and when to remove this message)
This may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. Please help improve it by replacing them with more appropriate citations to reliable, independent, third-party sources. (October 2014) (Learn how and when to remove this message)
This article needs more reliable medical references for verification or relies too heavily on primary sources. Please review the contents of the article and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed. Find sources: "Cycloastragenol" – news · newspapers · books · scholar · JSTOR (December 2013)
(Learn how and when to remove this message)
Cycloastragenol
Names
IUPAC name 24α,20-Epoxy-9,19-cyclo-9β-lanost-24-ene-3β,6α,16β,25-tetrol
Systematic IUPAC name (1R,2S,3aS,3bS,5S,5aR,7S,9aR,10aS,12aR)-1--3a,6,6,12a-tetramethyltetradecahydro-1H,10H-cyclopentacyclopropaphenanthrene-2,5,7-triol
Other names Cyclogalegigenin; Astramembrangenin
Identifiers
CAS Number
3D model (JSmol)
ChemSpider
PubChem CID
UNII
CompTox Dashboard (EPA)
InChI
  • InChI=1S/C30H50O5/c1-24(2)20(33)8-11-30-16-29(30)13-12-26(5)23(28(7)10-9-21(35-28)25(3,4)34)18(32)15-27(26,6)19(29)14-17(31)22(24)30/h17-23,31-34H,8-16H2,1-7H3/t17-,18-,19-,20-,21-,22-,23-,26+,27-,28+,29-,30+/m0/s1Key: WENNXORDXYGDTP-UOUCMYEWSA-N
  • InChI=1/C30H50O5/c1-24(2)20(33)8-11-30-16-29(30)13-12-26(5)23(28(7)10-9-21(35-28)25(3,4)34)18(32)15-27(26,6)19(29)14-17(31)22(24)30/h17-23,31-34H,8-16H2,1-7H3/t17-,18-,19-,20-,21-,22-,23-,26+,27-,28+,29-,30+/m0/s1Key: WENNXORDXYGDTP-UOUCMYEWBX
SMILES
  • CC(C)(O)1CC(C)(O1)3(O)C2(C)4C(O)6(C)(C)(O)CC65C45CC23C
Properties
Chemical formula C30H50O5
Molar mass 490.72 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). ☒N verify (what is  ?) Infobox references
Chemical compound

Cycloastragenol is a triterpenoid isolated from various legume species in the genus Astragalus that is purported to have telomerase activation activity. A preliminary in vitro study on human CD4 and CD8 T cells found that cycloastragenol may moderately increase telomerase activity and inhibit the onset of cellular senescence.

History

Cycloastragenol was patented by Geron Corporation and sold to Telomerase Activation Sciences in early 2013 who are developing it as a product named TA-65. Bill Andrews of Sierra Sciences has done testing on the anti-aging aspect of TA-65;, as well as Maria Blasco in the journal Aging Cell, finding no increase in murine median or mean lifespan but some physiological anti-aging effects without augmenting cancer incidence. TA sciences was served with a consent order by the Federal Trade Commission for deceptive advertising implying that TA-65 can reverse aging and repair DNA damage.

Potential pharmacology

Its mode of action is purported to be the activation of the human enzyme telomerase.

Cycloastragenol intake improved health span but not lifespan in normal mice.

As part of a study sponsored by RevGenetics, the cycloastragenol-based product TA-65 was tested by UCLA scientist Rita B. Effros and RevGenetics scientist Hector F. Valenzuela. The small study (using T-cells taken from 6 participants) found that TA-65 activated telomerase in cultured cells in all samples, while another Astragalus extract did not. The clinical significance of this work is uncertain.

Toxicity testing is limited and safety for the human consumer has not been adequately demonstrated. TA-65 was shown to improve biological markers associated with human health span through the lengthening of short telomeres and rescuing of old cells, although the significance of these findings in actual life expectancy is unknown. Publications in high-impact peer-reviewed journals are lacking however, and much of the online documentation supporting its use is sponsored by its manufacturers.

As disordered telomerase function is a feature of almost all cancers, there is an unproven, but theoretical risk of oncogene-mediated cancer promotion through the use of telomerase activators.

References

  1. ^ Valenzuela, Hector F; Fuller, Thomas; Edwards, Jim; Finger, Danielle; Molgora, Brenda (April 2009). "Cycloastragenol extends T cell proliferation by increasing telomerase activity". J Immunol. 182 (1_MeetingAbstracts): 90.30. doi:10.4049/jimmunol.182.Supp.90.30. S2CID 90199126. Retrieved 19 July 2015.
  2. Borrell, Brendan (2012-08-02). "Lawsuit challenges anti-ageing claims". Nature News. 488 (7409): 18. Bibcode:2012Natur.488...18B. doi:10.1038/488018a. PMID 22859181.
  3. "Application to market Cycloastragenol". acnfp.food.gov.uk. UK Advisory Committee on Novel Foods and Processes. Archived from the original on 2016-10-01. Retrieved 29 Nov 2017.
  4. Dr. Bill Andrews anti-aging test of TA-65
  5. ^ Bernardes; de Jesus, B; Schneeberger, K; Vera, E; Tejera, A; Harley, CB; Blasco, MA (2011). "The telomerase activator TA-65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence". Aging Cell. 10 (4): 604–21. doi:10.1111/j.1474-9726.2011.00700.x. PMC 3627294. PMID 21426483.
  6. "FTC Approves Final Consent Order in Telomerase Activation Sciences Deceptive Advertising Case". ftc.gov. Federal Trade Commission. 19 April 2018. Retrieved 28 January 2021.
  7. TA-65
  8. Valenzuela, Hector F; Effros, Rita B; Dimler, Taylor; Sweeney, Greg; Bateman, RileyH; Malgora, Brenda (14 January 2013). "Functional Assessment of Pharmacological Telomerase Activators in Human T Cells". Cells. 2 (1): 57–66. doi:10.3390/cells2010057. PMC 3972662. PMID 24709644.
  9. Harley, Calvin B; Liu, Weimin; Blasco, Maria; Vera, Elsa; Andrews, William H; Briggs, Laura A; Raffaele, Joseph M (1 February 2011). "A Natural Product Telomerase Activator As Part of a Health Maintenance Program". Rejuvenation Research. 14 (1): 45–56. doi:10.1089/rej.2010.1085. PMC 3045570. PMID 20822369.
  10. Shay, JW; Wright, WE (1 January 2001). "Telomeres and telomerase: implications for cancer and aging". Radiation Research. 155 (1 pt 2): 188–193. Bibcode:2001RadR..155..188S. doi:10.1667/0033-7587(2001)155[0188:tatifc]2.0.co;2. PMID 11121233. S2CID 10868585.
Categories: